In this randomized trials of 7554 patients with atrial fibrillation, who were not candidates for warfarin, and had at least 1 risk factor for stroke, were randomized to ASA or ASA + plavix. After 3.6 years follow, those in the combined group had lower risk of stroke (2.4% versus 3.3% per year) and lower risk of vascular events (stroke, MI, non-CNS emboli, or death) (6.8% versus 7.6% per year). Major bleeding (primarily GI bleeding) was more common in the combination group (2% versus 1.3% per year). In patients at low risk for GI bleeding, high risk for stroke, and no candidacy for warfarin, ASA + plavix is a reasonable alternative (abstract).
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
What comes to mind when you think of getting CME? I bet most of you would say sitting in an auditorium, whether that be during your local grand rounds or at our professional society meeting, like Hospital Medicine 16 in sunny San Diego this past March. Hanging out in the Twitterverse? Probably not so much… […]
As a nurse practitioner in hospital medicine I have multiple opportunities to interact with all sorts of physician hospitalist colleagues, hospital medicine group leaders, quality officers etc. Often their interactions with me take on a certain wary curiosity, like I am some exotic monkey or another creature that is unfamiliar to them. If I am […]